LV13289B - Synthetic peptides and uses thereof for the prevention and therapy of cancer invasion and metastasis - Google Patents

Synthetic peptides and uses thereof for the prevention and therapy of cancer invasion and metastasis Download PDF

Info

Publication number
LV13289B
LV13289B LVP-04-102A LV040102A LV13289B LV 13289 B LV13289 B LV 13289B LV 040102 A LV040102 A LV 040102A LV 13289 B LV13289 B LV 13289B
Authority
LV
Latvia
Prior art keywords
oligopeptide
metastasis
invasion
cancer
sequences
Prior art date
Application number
LVP-04-102A
Other languages
English (en)
Inventor
Matthias Rath
Aleksandra Niedzwiecki
Shrirang Netke
Original Assignee
Matthias Rath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matthias Rath filed Critical Matthias Rath
Publication of LV13289B publication Critical patent/LV13289B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (8)

  1. LV 13289 IZGUDROJUMA FORMULA 1. Oligopeptīds, kurā ietilpst oligopeptīda secība, kuru izvēlas no grupas, kas sastāv no: a) oligopeptīda secības, kā norādīts SEQ ID No:2; b) oligopeptīda, spējīga inducēt imūnreakciju pret epitopu ar SEQ ID No:2; c) 8-10 aminoskābju atlikumu oligopeptīda secības, kas satur vienu no secībām - a) vai b); d) oligopeptīda secības, kas satur vienu no oligopeptīda secībām - no a) līdz c), kur viena vai vairākas aminoskābes ir aizvietotas ar aminoskābēm ar vienādu lādiņu, izmēru un/vai hidrofobitāti, ar nosacījumu, ka oligopeptīda secība ir spējīga bloķēt vēža šūnu invāziju un metastāzi; e) oligopeptīda secības, kas satur vienu no oligopeptīda secībām - no a) līdz d), kur aminoskābes atlikums N- vai C-galā nav iekļauts, ar nosacījumu, ka oligopeptīda secība ir spējīga bloķēt vēža šūnu invāziju un metastāzi; un f) oligopeptīda secības, kas satur viena no oligopeptīda secību - no a) līdz e) vienu vai vairākus atkārtojumus, kas kovalenti saistīti viens ar otru.
  2. 2. Oligopeptīds saskaņā ar 1.punktu, kas atšķiras ar to, ka šis oligopeptīds ir savienots ar haptēnu, kas palielina imūnreakciju.
  3. 3. Farmaceitiska kompozīcija, kurā ietilpst oligopeptīds saskaņā ar 1. vai 2.punktu.
  4. 4. Diagnostiska kompozīcija, kurā ietilpst oligopeptīds saskaņā ar 1. vai 2.punktu.
  5. 5. Vakcīna, kurā ietilpst oligopeptīds saskaņā ar 1. vai 2.punktu.
  6. 6. Oligopeptīda saskaņā ar 1. vai 2.punktu pielietojums farmaceitiskas kompozīcijas iegūšanā vēža slimības, infekciju slimību, kardiovaskulāro slimību, deģeneratīvo slimību vai patoloģisko stāvokļu, saistītu ar ECM destrukciju ar MMPs, profilaksei vai ārstēšanai.
  7. 7. Pielietojums saskaņā ar 6.punktu, kas atšķiras ar to, ka farmaceitisko kompozīciju ievada slimniekam vakcīnas, injekcijas, infūzijas, inhalācijas vai supozitorija veidā.
  8. 8. Pielietojums saskaņā ar 6. vai 7.punktu, kas atšķiras ar to, ka šo oligopeptīdu ievada koncentrācijas intervālā no 1 μΜ līdz 500 μΜ vai no 50 μΜ līdz 200 μΜ
LVP-04-102A 2002-01-23 2004-09-17 Synthetic peptides and uses thereof for the prevention and therapy of cancer invasion and metastasis LV13289B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35131702P 2002-01-23 2002-01-23

Publications (1)

Publication Number Publication Date
LV13289B true LV13289B (en) 2005-11-20

Family

ID=27613485

Family Applications (2)

Application Number Title Priority Date Filing Date
LVP-04-102A LV13289B (en) 2002-01-23 2004-09-17 Synthetic peptides and uses thereof for the prevention and therapy of cancer invasion and metastasis
LVP-05-134A LV13419B (en) 2002-01-23 2005-10-17 Synthetic peptides and uses thereof for the prevention and therapy of cancer invasion and metastasis

Family Applications After (1)

Application Number Title Priority Date Filing Date
LVP-05-134A LV13419B (en) 2002-01-23 2005-10-17 Synthetic peptides and uses thereof for the prevention and therapy of cancer invasion and metastasis

Country Status (22)

Country Link
US (1) US8012935B2 (lv)
EP (1) EP1468085B1 (lv)
JP (1) JP2005515262A (lv)
KR (1) KR20040077764A (lv)
CN (2) CN1622992A (lv)
AT (1) ATE425247T1 (lv)
BR (1) BR0302819A (lv)
CA (1) CA2472775A1 (lv)
DE (1) DE60326539D1 (lv)
EE (1) EE200400030A (lv)
ES (1) ES2324027T3 (lv)
HR (1) HRP20040732A2 (lv)
IL (1) IL162714A0 (lv)
LV (2) LV13289B (lv)
MX (1) MXPA04007170A (lv)
NO (1) NO20034146L (lv)
NZ (1) NZ533738A (lv)
PL (1) PL209827B1 (lv)
RU (1) RU2346043C2 (lv)
WO (1) WO2003062413A1 (lv)
YU (1) YU76403A (lv)
ZA (1) ZA200405328B (lv)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2856598B1 (fr) * 2003-06-25 2005-10-28 Inst Nat Sante Rech Med Peptides derives de la proteine mmp-2 et leur utilisation en immunotherapie antitumorale
JP4911950B2 (ja) * 2005-11-07 2012-04-04 晃 伊東 Ｍｍｐ−１の部分ペプチドを用いた癌浸潤・転移阻害薬
EP2403508B1 (en) * 2009-03-06 2015-10-28 Université Paris Descartes Method of treating cancer employing gingival fibroblast conditioned medium
US8593732B1 (en) * 2010-01-23 2013-11-26 Lightsmyth Technologies, Inc. Partially metallized total internal reflection immersion grating
US8003110B1 (en) * 2011-01-24 2011-08-23 Matthias W. Rath Metalloproteinase oligopeptides and their therapeutic use
EP2649985A1 (en) * 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
US20140017267A1 (en) * 2012-07-13 2014-01-16 Matthias W Rath Metalloproteinase oligopeptides and their therapeutic use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5280106A (en) 1988-05-20 1994-01-18 Liotta Lance A Matrix metalloproteinase peptides: role in diagnosis and therapy
GB8817075D0 (en) * 1988-07-18 1988-08-24 Raychem Ltd Oscillation suppressor
US5646027A (en) * 1994-09-08 1997-07-08 Warner-Lambert Company Process for the production of gelatinase catalytic domain protein
ES2559317T3 (es) 1999-10-29 2016-02-11 Glaxosmithkline Biologicals Sa Péptidos antigénicos de Neisseria

Also Published As

Publication number Publication date
EP1468085B1 (en) 2009-03-11
NO20034146L (no) 2003-10-28
PL209827B1 (pl) 2011-10-31
ES2324027T3 (es) 2009-07-29
ZA200405328B (en) 2006-03-29
RU2004125599A (ru) 2005-07-10
NZ533738A (en) 2006-03-31
JP2005515262A (ja) 2005-05-26
HRP20040732A2 (en) 2005-06-30
US20030139345A1 (en) 2003-07-24
PL371254A1 (en) 2005-06-13
MXPA04007170A (es) 2004-10-29
CN1622992A (zh) 2005-06-01
US8012935B2 (en) 2011-09-06
CA2472775A1 (en) 2003-07-31
ATE425247T1 (de) 2009-03-15
RU2346043C2 (ru) 2009-02-10
LV13419B (en) 2006-09-20
DE60326539D1 (de) 2009-04-23
KR20040077764A (ko) 2004-09-06
WO2003062413A1 (en) 2003-07-31
YU76403A (sh) 2006-05-25
CN101007844A (zh) 2007-08-01
EP1468085A1 (en) 2004-10-20
IL162714A0 (en) 2005-11-20
EE200400030A (et) 2004-04-15
NO20034146D0 (no) 2003-09-17
BR0302819A (pt) 2004-04-27

Similar Documents

Publication Publication Date Title
JP4846799B2 (ja) 腫瘍の治療
US7635682B2 (en) Tumor activated prodrugs
US7192929B2 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
LV13419B (en) Synthetic peptides and uses thereof for the prevention and therapy of cancer invasion and metastasis
US7374898B2 (en) Peptide inhibitors against seprase
CA2929637A1 (en) Use of il-22 dimers in manufacture of medicaments for treating pancreatitis
EP2580237A1 (en) Novel peptides for wound healing
US20230158100A1 (en) Treatment of panx1 associates diseases
EP3233110B1 (en) Cyclic acetylcholinesterase c-terminal peptide in the treatment or prevention of cancer or metastasis
AU2003205658A1 (en) Synthetic peptides and uses thereof for the prevention and therapy of cancer invasion and metastasis
JP2019522046A (ja) 変形性関節症の治療のためのペプチド
ZA200104130B (en) Inhibition of angiogenesis by high molecular weight kininogen and peptide analogs thereof.
LT5328B (lt) Sintetiniai peptidai ir jų panaudojimas vėžio invazijos ir metastazių gydymui ir profilaktikai
WO2011068853A2 (en) TREATMENT OF IgE-MEDIATED DISEASE
EP2244719A1 (en) Wound healing peptides and methods of use thereof
WO2024031022A2 (en) Peptide compositions and methods of use
WO2023183667A1 (en) Urokinase-type plasminogen activator receptor binding peptides and methods of use
JPH08183740A (ja) 細胞接着阻害剤及び該阻害剤を含む抗炎症剤